Member Info for Takayama

I’m annoyed the Mail on Sunday published that article. I’ve some cash coming to me soon and I was hoping to pick this up on the cheap. At least before the Unilever royalty was announced. Unlikely to be that I have any spare cash to buy at sub 0.6 now. This is likely to climb tomorrow also given the climb today. Possibly up to 0.8.

Gotta say that Keir is really playing a blinder on the foreign policy front. He has Trump eating out of his hand! And Trump is reengaging on Ukraine too. All thanks to our Keir! That can only be good for Lloyds! And undoubtedly the main reason behind the share price rise. All of us shareholders should be paying our respects to such a great leader! So much better than the years of stagnation and misery under the tories.

I do t think it’s necessarily a bad thing if Sidara don’t bid. Like others have pointed out, there’s a viable business here. I doubt the FCA will find anything useful, and it may lead to the resignation of Gilmartin. I’ve met a few CEOs of blue chips and the interesting thing is that they are ordinary mortals earning a fair whack. The best of them make the most common sense decisions and take responsibility. That’s pretty much it. No Sidara bid, FCA investigation leading to Gilmartin’s resignation (essentially it’s about governance than criminality, and as others have pointed out, they’re much like a toothless three legged cat lol!), and that’ll be the way out. I haven’t kept track about debt finance but I assume that’s likely to be easily sorted given the recent contract announcements. The industry does seem to feel positive about Wood. Problems are very much about governance and culture, not criminality.

I’d be surprised if sidara do bid now. It’s quite a lot of risk that’s quite hard to quantify, so their company is hard to value at this point.

Anyone else thought this was significant news?

"With proving and testing expected be completed before the end of this year, Aptamer sees potential for signing of a licensing agreement with Unilever during its FY 25/26". It goes on to explain that the pipeline to commercialisation is less than pharmaceuticals given 'ingredient dosage limitations and dosage ratios' of their deodorant are already compliant.

That's from the Turner Pope note. It goes on to provide the data for us to speculate about how much this could bring Aptamer!

So the cash pipeline is enough to ensure survival without a cash call before the Unilever licensing agreement. It'll be a blow if the human testing that Unilever are currently doing throws something up that the lab tests didn't spot. But what are the chances of that? "Trials of the binders with human skin samples originally began in Q4 2024.." so I'd say we've a really good chance of the human testing not throwing up any curve balls at this stage given Unilever and Aptamer have just signed this deal - and we're so many months on into 2025, into the human trials.... .

So, GLA! Aptamer really do look like they will provide me with that fair dose of good news I am owed! Lol!

Funding was the issue here and whether there was enough of a cash pipeline to survive. That's what drove the SP down so low from 100p to the ridiculous levels we've seen the last 12 months. The turnaround that started around this time last year has proved its worth. The last Turner Pope analyst note around two months ago identified enough cash to June 2026 - 12 months away. This new deal provides funding to way beyond that and more time to allow for the rest of the winning business model (which allows for royalties to fund Aptamer) to kick in. As we know, we're on the cusp of those deals. More than ever, this looks like a buy. And I mean MORE THAN EVER - even when Aptamer was floated at 100p.

UK economy is on the turnaround after so many years of Tory mismanagement by incompetents. All these trade deals only spell success for the banking sector!

Trade deal after trade deal! No wonder the sp is up!

It makes a refreshing change to finally get at the front end of a multi bagger. The breadth of IP this company is likely to get is increasing, it's a decent business model, a good team (at last), and it seems to be on track to finally make good. Out of all my portfolio, I'm perhaps most pleased that I'm invested here. Hopefully this will be the one that pays off the mortgage! Lol!

Essentially repeating everything everyone says, so no new news, but new analysis. It's a useful bit of analysis and I'd encourage you to get a free account with Turner Pope yourself to get the full report:

Along with today’s important product news, FFS contracts and licensing agreement, recent months have also seen

strategic developments with Unilever and Neuro-Bio advancing through key milestones and technological

validation, while also achieving a state of final commercial preparedness for another Optimer® delivery vehicle that

is being tested with the Group’s genetics medicine partner. Taken altogether, this progress continues to enhance

Aptamer’s portfolio of assets as it moves incrementally closer to a value inflection point(s) with heightening

licensing potential. Revenue recognition also continues to increase, supported by a robust pipeline of FFS projects

and opportunities as they advance through the Group’s laboratories. Such contracts can sometimes take extended

periods to negotiate with its lengthening list of customers, primarily because Aptamer insists on securing the best

contractual terms and conditions to ensure all agreements capture the best long-term growth potential and

prospective licensing returns. Based nevertheless on simply being able to sustain its existing trajectory of incoming

FFS work and having completed the scale back of its cost base, the Board continues to project cash-in-hand (incl.

annual R&D tax credits) will be sufficient to satisfy working capital needs out to end-June 2026, by which time

anticipated first collection of milestone payments, licensing fees and/or royalties offer potential for it to become

financially self-sustaining going forward. Although such passive income, which could commence during the

current calendar year, is initially likely to be modest, there is scope for it to multiply substantially thereafter.

Seemingly unrecognised in the Group’s current valuation, any such breakthrough adoption(s) would be

transformative for Aptamer, both financially and in terms of reputation.

Brilliant work by Starmer and the team in carefully gliding the UK economy into calmer waters.

Such a successful buyback couldn’t have happened without a strong stable government focused on growth of the economy

I don’t think you underage word ‘troll’ bloomers. lol!

Towards growth! lol!

What a brilliant job Keir and his team have done e in repositioning the UK towards chaos after the chaos brought about by 13 years of the tories trying to imitate UKIP/Reform! A brighter future for the UK economy at last! And with the net zero agenda, we will also lead in saving the world!

The slowly dying gearbox had nothing left and needed a change-the most apt thing that Ed has said for about a year, if not more

\ok, I posted too quickly! Let's see what comes out of admin... .

It hasn't gone into admin. It's suspension. Could be any variety of reasons. Maybe yesterday's tick up offered a hint. Or it could be suspension. At least the wait is over! Lol! Old story - Serica, suspended at 7p, relisted around 80p following reverse takeover. That was a result! There, you invested in the leadership.. .

I don't expect much either today except for suspension, and having been there before, I am content. It's a completely understandable position. What I do know is the company is throwing EVERYTHING at fulfilling Sidara's conditions. I don't see it too much as a casino. In a company like Wood, people will have bent the rules, they won't have flat out invented completely wild material for the accounts. So my expectation at this point is a 35p offer to come. It's a great time to buy if you've spare cash I'd say. Compared to other things on the market, this offers a good risk/reward ratio.